
Unaudited Interim Results

FOR THE SIX MONTHS ENDED 31 DECEMBER 2012

AFROCENTRIC GROU



Number of ord

Number of pre

Weighted avera

(cents)

(cents)

(cents)

(cents) (Note 3)

Headline earnings per share

Attributable to ordinary shares

Diluted earnings per share (cents) (as reported) (Note 2)

Normalised earnings per share

Diluted normalised earnings

per share (cents) (Note 3)

Diluted earnings per share

per share (cents) (Note 3)

issue

OUR PEOPLE OUR PASSION

AfroCentric commenced business during 2007 and has since invested in businesses that demonstrate good prospects for growth, with the objective of contributing to the upliftment of South Africa's people in a meaningful and sustainable manner.

The Group's subsidiary, AfroCentric Health enjoys a unique status in the healthcare sector, having a Level 2 BBBEE rating.

The Board of Directors has pleasure in presenting the Group's unaudited results for the six month period ended 31 December 2012. The Group's overall performance for the period under review has been satisfactory, once again achieving positive growth in earnings, while simultaneously contributing to a world of affordable and sustainable healthcare, these objectives being cornerstones of the Group's strategy.

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

EQUITY AND LIABILITIESCapital and reserves924 842Issued capital352 669Contingent shares to be issued188 540Share-based awards reserve20 759Treasury shares(2 701)Foreign currency translation reserve(171)Obstributable reserve365 746Yon-controlling interest38 449Total equity963 290Non-current liabilities278 685Deferred income tax liabilities51 846Borrowings200 000Provisions3 504Accrual for straight lining of leases14 985Current liabilities153 591Borrowings7 181Provisions7 181Provisions92 641Borrowings92 641Foreign current transpatient90 87Encode the payables7 86Station3 000A 239Bank overdraft-Employment benefit provisions53 766Station53 766 <t< th=""><th>-</th><th>Unaudited ix months ended I December 2012 R'000</th><th>Unaudited six months ended 31 December 2011 R'000</th><th>Audited year ended 30 June 2012 R'000</th></t<>	-	Unaudited ix months ended I December 2012 R'000	Unaudited six months ended 31 December 2011 R'000	Audited year ended 30 June 2012 R'000
Investment property Intangible assets 10 300 10 100 Interpretation 661 007 609 926 Unlisted investments 280 280 Investment in associates 88 470 62 368 Investment in preference shares 100 000 100 000 Deferred income tax assets 71 626 59 116 Current assets 367 746 241 966 Trade and other receivables 116 733 94 685 Receivables from associates and joint 12 260 18 647 ventures 208 997 120 653 Current tax asset 29 756 7 981 Cash and cash equivalents 208 997 120 653 Total assets 1 395 566 1 183 804 1 EQUITY AND LIABILITIES 20 20 759 - Contingent shares to be issued 188 540 188 540 Share-based awards reserve 20 759 - Treasury shares (2 701) (1 162) Foreign currency translation reserve 217 644 223 588 Non-current liabilities <td>nt assets</td> <td>1 027 820</td> <td>941 838</td> <td>991 884</td>	nt assets	1 027 820	941 838	991 884
Intangible assets 661 007 609 926 Unlisted investments 280 280 Investment in preference shares 100 000 100 000 Deferred income tax assets 367 746 241 966 Trade and other receivables 367 746 241 966 Receivables from associates and joint ventures 29 756 7 981 Cash and cash equivalents 208 997 120 653 Total assets 1 395 566 1 183 804 1 EQUITY AND LIABILITIES 29 24 842 758 355 183 904 1 Equity And reserves 924 842 758 355 183 904 1 Contingent shares to be issued 188 540 188 540 188 540 Share-based awards reserve (2 701) (1 1 162) 1064 Foreign currency translation reserve (171) (327) 105tributable reserve 38 449 17 694 Non-current liabilities 278 685 270 376 104 104 Poreign currency translation reserve (2 701) 76 649 122 104 122 N	ant and equipment	96 137	100 048	97 016
Unlisted investments 280 280 Investment in preference shares 88 470 62 368 Investment in preference shares 100 000 100 000 Deferred income tax assets 367 746 241 966 Current assets 367 746 241 966 Trade and other receivables 116 733 94 685 Receivables from associates and joint ventures 12 260 18 647 Current tax asset 29 756 7 981 Cash and cash equivalents 208 997 120 653 Total assets 1 395 566 1 183 804 1 EQUITY AND LIABILITIES 200 2759 - Contingent shares to be issued 188 540 188 540 Share-based awards reserve 20 759 - Treasury shares (2 701) (1 162) Foreign currency translation reserve 365 746 223 588 Non-controlling interest 38 449 17 694 Total equity 963 290 776 049 Non-current liabilities 51 846 35 031 Borrowings </td <td>property</td> <td>10 300</td> <td>10 100</td> <td>10 300</td>	property	10 300	10 100	10 300
Investment in associates 88 470 62 368 Investment in preference shares 100 000 100 000 Deferred income tax assets 367 746 241 966 Current assets 367 746 241 966 Trade and other receivables 116 733 94 685 Receivables from associates and joint ventures 29 756 7 981 Current tax asset 29 756 7 981 Cash and cash equivalents 208 997 120 653 Total assets 1 395 566 1 183 804 1 EQUITY AND LIABILITIES 208 997 120 653 Issued capital 352 669 347 716 Contingent shares to be issued 188 540 188 540 Share-based awards reserve 20 759 - Treasury shares (2 701) (1 162) Foreign currency translation reserve 20 776 049 Non-controlling interest 38 449 17 694 Total equity 963 290 776 649 Non-current liabilities 51 846 35 031 Borrowings 200 000	ssets	661 007	609 926	611 042
Investment in preference shares 100 000 100 000 Deferred income tax assets 367 746 241 966 Trade and other receivables 116 733 94 685 Receivables from associates and joint ventures 12 260 18 647 Current tax asset 29 756 7 981 Cash and cash equivalents 208 997 120 653 Total assets 1 395 566 1 183 804 1 EQUITY AND LIABILITIES 20 759 - - Capital and reserves 924 842 758 355 - Issued capital 352 669 347 716 - Contingent shares to be issued 188 540 188 540 188 540 Share-based awards reserve 20 759 - - Treasury shares (2 701) (1 162) - Foreign currency translation reserve 36 57 46 223 588 - Non-controlling interest 38 449 17 694 - Total equity 963 290 776 049 - Non-current liabilities 51 846 35 0	estments		280	280
Deferred income tax assets 71 626 59 116 Current assets 367 746 241 966 Trade and other receivables 116 733 94 685 Receivables from associates and joint ventures 12 260 18 647 Current tax asset 29 756 7 981 Cash and cash equivalents 208 997 120 653 Total assets 1 395 566 1 183 804 1 EQUITY AND LIABILITIES 200 9759 - - Capital and reserves 924 842 758 355 - Issued capital 352 669 347 716 - Contingent shares to be issued 188 540 188 540 - Share-based awards reserve 20 759 - - Treasury shares (2 701) (1 162) - Foreign currency translation reserve 20 756 23 588 Non-controlling interest 38 449 17 694 Total equity 963 290 776 049 Non-current liabilities 51 846 35 031 Borrowings 20 000				86 765
Current assets367 746241 966Trade and other receivables116 73394 685Receivables from associates and joint ventures12 26018 647Current tax asset29 7567 981Cash and cash equivalents208 997120 653Total assets1 395 5661 183 8041EQUITY AND LIABILITIES208 997120 653Capital and reserves924 842758 355Issued capital352 669347 716Contingent shares to be issued188 540188 540Share-based awards reserve20 759-Treasury shares(2 701)(1 162)Foreign currency translation reserve365 746223 588Non-controlling interest38 44917 694Total equity963 290776 049Non-current liabilities278 685270 376Deferred income tax liabilities218 44635 031Borrowings200 000200 000Provisions3 5043 821Accrual for straight lining of leases13 591137 379BorrowingsProvisions7 1812 073Trade and other payables92 64169 954Taxation3 0004 239Bank overdraft-9 087Employment benefit provisions53 76652 026				100 000
Trade and other receivables116 73394 685Receivables from associates and joint ventures12 26018 647Current tax asset29 7567 981Cash and cash equivalents208 997120 653Total assets1 395 5661 183 8041EQUITY AND LIABILITIES20 759-Capital and reserves924 842758 355Issued capital352 669347 716Contingent shares to be issued188 540Share-based awards reserve20 759-Treasury shares(2 701)(1 162)Foreign currency translation reserve365 746223 588Non-controlling interest38 44917 694Total equity963 290776 049Non-current liabilities51 84635 031Borrowings200 000200 000Provisions8 3509 215Post-employment medical obligations3 5043 821Accrual for straight lining of leases14 98522 309Current liabilities153 591137 379BorrowingsProvisions7 1812 073Trade and other payables92 64169 954Taxation3 0004 239Bank overdraft-9 087Employment benefit provisions53 76652 026	ome tax assets	71 626	59 116	86 481
Receivables from associates and joint ventures12 26018 647Current tax asset29 7567 981Cash and cash equivalents208 997120 653Total assets1 395 5661 183 8041EQUITY AND LIABILITIESCapital and reserves924 842758 355Issued capital352 669347 716Contingent shares to be issued188 540188 540Share-based awards reserve20 759-Treasury shares(2 701)(1 162)Foreign currency translation reserve(171)(327)Distributable reserve365 746223 588Non-courrent liabilities278 685270 376Deferred income tax liabilities51 84635 031Borrowings200 000200 000Provisions8 3509 215Post-employment medical obligations3 5043 821Accrual for straight lining of leases14 98522 309Current liabilities153 591137 379BorrowingsProvisions7 1812 073Trade and other payables3 0004 239Bank overdraft-9 087Employment benefit provisions53 76652 026	sets	367 746	241 966	371 416
Receivables from associates and jointCurrent tax asset29 756Current tax asset208 997Cash and cash equivalents1395 566Total assets1 395 566Issued capital352 669Contingent shares to be issued188 540Share-based awards reserve20 759Treasury shares(2 701)Foreign currency translation reserve(1711)Distributable reserve365 746Distributable reserve365 746Non-controlling interest78 685Deferred income tax liabilities51 846Borrowings200 000Provisions3 504Post-employment medical obligations3 504Accrual for straight lining of leases14 985Current liabilities153 591Borrowings-Provisions7 181Provisions9 2641Post-employment medical obligations3 0004 2393 000Accrual for straight lining of leases-14 98522 309Current liabilities153 591Borrowings-Provisions7 1812 073-Trade and other payables92 6416 9 954Taxation3 000Aczage-9 087Employment benefit provisions53 76652 026				108 511
208 997 120 653 Total assets 1 395 566 1 183 804 1 EQUITY AND LIABILITIES - - - Capital and reserves 924 842 758 355 - Issued capital 352 669 347 716 - Contingent shares to be issued 188 540 188 540 - Share-based awards reserve 20 759 - - Treasury shares (2 701) (1 162) - Foreign currency translation reserve (171) (327) - Distributable reserve 365 746 223 588 - Non-controlling interest 38 449 17 694 - Total equity 963 290 776 049 - Non-current liabilities 51 846 35 031 - Borrowings 200 000 200 000 - - Provisions 8 350 9 215 - - Post-employment medical obligations 3 504 3 821 - - Accrual for straight lining	from associates and joint	12 260	18 647	14 591
Classifier 1 395 566 1 183 804 1 EQUITY AND LIABILITIES 224 842 758 355 Issued capital 352 669 347 716 Contingent shares to be issued 188 540 188 540 Share-based awards reserve 20 759 - Treasury shares (2 701) (1 162) Foreign currency translation reserve 365 746 223 588 Non-controlling interest 38 449 17 694 Total equity 963 290 776 049 Non-current liabilities 278 685 270 376 Deferred income tax liabilities 51 846 35 01 Borrowings 200 000 200 000 200 000 Provisions 8 350 9 215 Post-employment medical obligations 3 504 3 821 Accrual for straight lining of leases 13 95 591 137 379 Borrowings 7 181 2 073 Provisions 7 181 2 073 Trade and other payables 9 087 9 087 Employment benefit provisions 53 766	asset			6 404
EQUITY AND LIABILITIESCapital and reserves924 842Issued capital352 669Contingent shares to be issued188 540Share-based awards reserve20 759Treasury shares(2 701)Foreign currency translation reserve(171)Uistributable reserve365 746Share-based awards reserve365 746Poreign currency translation reserve(1711)Uistributable reserve365 746Non-controlling interest38 449Total equity963 290Non-current liabilities278 685Deferred income tax liabilities51 846Borrowings200 000Provisions3 504Accrual for straight lining of leases14 985Current liabilities153 591Distributable71 81Provisions7 181Provisions3 000Accrual for traight lining of leases92 641Barrowings-Provisions7 181Provisions9 2641Station3 000Action3 000Bark overdraft-Station53 766Station53 766Station	sh equivalents	208 997	120 653	241 910
Capital and reserves 924 842 758 355 Issued capital 352 669 347 716 Contingent shares to be issued 188 540 188 540 Share-based awards reserve 20 759 - Treasury shares (2 701) (1 162) Foreign currency translation reserve (1711) (327) Distributable reserve 365 746 223 588 Non-controlling interest 38 449 17 694 Total equity 963 290 776 049 Non-current liabilities 278 685 270 376 Deferred income tax liabilities 51 846 35 031 Borrowings 200 000 200 000 Provisions 8 350 9 215 Post-employment medical obligations 3 504 3 821 Accrual for straight lining of leases 14 985 22 309 Current liabilities 153 591 137 379 Borrowings 7 181 2 073 Trade and other payables 7 202 641 Trade and other payables 3 000 4 239	ts	1 395 566	1 183 804	1 363 300
Issued capital 352 669 347 716 Contingent shares to be issued 188 540 188 540 Share-based awards reserve 20 759 - Treasury shares (2 701) (1 162) Foreign currency translation reserve (2 701) (327) Distributable reserve 365 746 223 588 Non-controlling interest 38 449 17 694 Total equity 963 290 776 049 Non-current liabilities 278 685 270 376 Deferred income tax liabilities 51 846 35 031 Borrowings 200 000 200 000 Provisions 8 350 9 215 Post-employment medical obligations 3 504 3 821 Accrual for straight lining of leases 14 985 22 309 Current liabilities 153 591 137 379 Borrowings 7 181 2 073 Provisions 7 181 2 073 Trade and other payables 3 000 4 239 Bank overdraft 9 087 9 087 Employme	ND LIABILITIES			
Contingent shares to be issued 188 540 Share-based awards reserve 20 759 Treasury shares (2 701) Foreign currency translation reserve (1711) Distributable reserve 365 746 Non-controlling interest 38 449 Total equity 963 290 Non-current liabilities 278 685 Deferred income tax liabilities 51 846 Borrowings 200 000 Provisions 8 350 Accrual for straight lining of leases 133 594 Current liabilities 133 591 Borrowings 7 181 Provisions 7 181 Provisions 7 181 Provisions 3 000 Accrual for the payables 92 641 Bark overdraft 9 087 Employment benefit provisions 53 766	d reserves	924 842	758 355	882 815
Share-based awards reserve 20 759 - Treasury shares (2 701) (1 162) Foreign currency translation reserve (1711) (327) Distributable reserve 365 746 223 588 Non-controlling interest 38 449 17 694 Total equity 963 290 776 049 Non-current liabilities 2178 685 270 376 Deferred income tax liabilities 51 846 35 031 Borrowings 200 000 200 000 Provisions 8 350 9 215 Post-employment medical obligations 3 504 3 821 Accrual for straight lining of leases 14 985 22 309 Current liabilities 153 591 137 379 Borrowings 7 181 2 073 Trade and other payables 3 000 4 239 Bank overdraft 9 087 9 087 Employment benefit provisions 53 766 52 026	al	352 669	347 716	349 365
Treasury shares (2 701) (1 162) Foreign currency translation reserve (171) (327) Distributable reserve 365 746 223 588 Non-controlling interest 38 449 17 694 Total equity 963 290 776 049 Non-current liabilities 278 685 270 376 Deferred income tax liabilities 51 846 35 031 Borrowings 200 000 200 000 Provisions 8 350 9 215 Post-employment medical obligations 3 504 3 821 Accrual for straight lining of leases 14 985 22 309 Current liabilities 153 591 137 379 Borrowings 7 181 2 073 Trade and other payables 3 200 4 239 Bank overdraft 9 087 9 087 Employment benefit provisions 53 766 52 026	shares to be issued	188 540	188 540	188 540
Foreign currency translation reserve (171) (327) Distributable reserve 365 746 223 588 Non-controlling interest 38 449 17 694 Total equity 963 290 776 049 Non-current liabilities 278 685 270 376 Deferred income tax liabilities 51 846 35 031 Borrowings 200 000 200 000 Provisions 8 350 9 215 Post-employment medical obligations 3 504 3 821 Accrual for straight lining of leases 14 985 22 309 Current liabilities 153 591 137 379 Borrowings 7 181 2 073 Trade and other payables 3 000 4 239 Bank overdraft 9 087 9 087 Employment benefit provisions 53 766 52 026	awards reserve	20 759	-	9 357
Distributable reserve 365 746 223 588 Non-controlling interest 38 449 17 694 Total equity 963 290 776 049 Non-current liabilities 278 685 270 376 Deferred income tax liabilities 51 846 35 031 Borrowings 200 000 200 000 Provisions 8 350 9 215 Post-employment medical obligations 3 504 3 821 Accrual for straight lining of leases 14 985 22 309 Current liabilities 153 591 137 379 Borrowings - - Provisions 7 181 2 073 Trade and other payables 3 000 4 239 Bank overdraft - 9 087 Employment benefit provisions 53 766 52 026	ires	(2 701)	(1 162)	(1 772)
Non-controlling interest 38 449 17 694 Total equity 963 290 776 049 Non-current liabilities 278 685 270 376 Deferred income tax liabilities 51 846 35 031 Borrowings 200 000 200 000 Provisions 8 350 9 215 Post-employment medical obligations 3 504 3 821 Accrual for straight lining of leases 14 985 22 309 Current liabilities 153 591 137 379 Borrowings 7 181 2 073 Trade and other payables 92 641 69 954 Taxation 3 000 4 239 Bank overdraft 9 087 9 087 Employment benefit provisions 53 766 52 026	ency translation reserve	(171)	(327)	(646)
Total equity 963 290 776 049 Non-current liabilities 278 685 270 376 Deferred income tax liabilities 51 846 35 031 Borrowings 200 000 200 000 Provisions 8 350 9 215 Post-employment medical obligations 3 504 3 821 Accrual for straight lining of leases 14 985 22 309 Current liabilities 153 591 137 379 Borrowings 7 181 2 073 Trade and other payables 92 641 69 954 Taxation 3 000 4 239 Bank overdraft 9 087 9 087 Employment benefit provisions 53 766 52 026				337 971
Non-current liabilities 278 685 270 376 Deferred income tax liabilities 51 846 35 031 Borrowings 200 000 200 000 Provisions 8 350 9 215 Post-employment medical obligations 3 504 3 821 Accrual for straight lining of leases 14 985 22 309 Current liabilities 153 591 137 379 Borrowings 7 181 2 073 Provisions 7 181 2 073 Trade and other payables 92 641 69 954 Taxation 3 000 4 239 Bank overdraft 9 087 9 087 Employment benefit provisions 53 766 52 026	-			30 625
Deferred income tax liabilities 51 846 35 031 Borrowings 200 000 200 000 Provisions 8 350 9 215 Post-employment medical obligations 3 504 3 821 Accrual for straight lining of leases 14 985 22 309 Current liabilities 153 591 137 379 Borrowings - - Provisions 7 181 2 073 Trade and other payables 92 641 69 954 Taxation 3 000 4 239 Bank overdraft - 9 087 Employment benefit provisions 53 766 52 026	ty	963 290	776 049	913 440
Borrowings 200 000 200 000 Provisions 8 350 9 215 Post-employment medical obligations 3 504 3 821 Accrual for straight lining of leases 14 985 22 309 Current liabilities 153 591 137 379 Borrowings - - Provisions 7 181 2 073 Trade and other payables 92 641 69 954 Taxation 3 000 4 239 Bank overdraft - 9 087 Employment benefit provisions 53 766 52 026	nt liabilities	278 685	270 376	271 968
Provisions8 3509 215Post-employment medical obligations3 5043 821Accrual for straight lining of leases14 98522 309Current liabilities153 591137 379Borrowings71812 073Trade and other payables92 64169 954Taxation3 0004 239Bank overdraft-9 087Employment benefit provisions53 76652 026	ome tax liabilities	51 846	35 031	47 595
Post-employment medical obligations3 5043 821Accrual for straight lining of leases14 98522 309Current liabilities153 591137 379BorrowingsProvisions7 1812 073Trade and other payables92 64169 954Taxation3 0004 239Bank overdraft-9 087Employment benefit provisions53 76652 026				200 000
Accrual for straight lining of leases 14 985 22 309 Current liabilities 153 591 137 379 Borrowings - - Provisions 7 181 2 073 Trade and other payables 92 641 69 954 Taxation 3 000 4 239 Bank overdraft - 9 087 Employment benefit provisions 53 766 52 026				8 350
Current liabilities 153 591 137 379 Borrowings - - Provisions 7 181 2 073 Trade and other payables 92 641 69 954 Taxation 3 000 4 239 Bank overdraft - 9 087 Employment benefit provisions 53 766 52 026	0			3 504
Borrowings - Provisions 7 181 2 073 Trade and other payables 92 641 69 954 Taxation 3 000 4 239 Bank overdraft - 9 087 Employment benefit provisions 53 766 52 026		14 985	22 309	12 519
Provisions 7 181 2 073 Trade and other payables 92 641 69 954 Taxation 3 000 4 239 Bank overdraft - 9 087 Employment benefit provisions 53 766 52 026	bilities	153 591	137 379	177 892
Trade and other payables 92 641 69 954 Taxation 3 000 4 239 Bank overdraft - 9 087 Employment benefit provisions 53 766 52 026		-	-	8 346
Taxation 3 000 4 239 Bank overdraft - 9 087 Employment benefit provisions 53 766 52 026				8 779
Bank overdraft 9 087 Employment benefit provisions 53 766	ther payables			76 802
Employment benefit provisions 53 766 52 026	off	3 000		4 149
Total liabilities 432.276 407.755		53 766		79 816
407755	ities	432 276	407 755	449 860
Total equity and liabilities 1 395 566 1 183 804 1	ty and liabilities	1 395 566	1 183 804	1 363 300

CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME							
		Unaudited	Unaudited	Audited year			
		six months ended 31	six months ended	ended			
	%	December 2012	31 December 2011	30 June 2012			
	change	R'000	R'000	R'000			
Revenue	22.75%	822 422	670 007	1 448 261			

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

	Unaudited six months ended 31 December 2012 R'000	Unaudited six months ended 31 December 2011 R'000	Audited year ended 30 June 2012 R'000
Balance at beginning of the period	913 440	747 635	747 635
Issue of share capital	3 304	3 931	5 579
Share-based awards reserve	11 402	-	9 357
Revaluation of treasury shares issued	(929)	-	(609)
Dividends reclaimed and subsidiary acquisitions	-	-	5 868
Foreign currency translation reserve	476	(568)	(887)
Dividends paid/Distribution to shareholders	(33 218)	(33 884)	(33 884)
Net profit for the year	59 529	54 344	164 506
Profit attributable to minorities	9 286	4 591	15 875
Balance at end of period	963 290	776 049	913 440

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

	% change	Unaudited six months ended 31 December 2012 R'000	Unaudited six months ended 31 December 2011 R'000	Audited year ended 30 June 2012 R'000
Net cash inflow/(outflow) in operating activities		74 977	(11 947)	116 236
Net cash inflow/(outflow) from investing activities		(70 096)	(24 854)	(55 353)
Net cash inflow/(outflow) from financing activities		(37 794)	(24 344)	8 315
Net (decrease)/increase in cash and cash equivalents	-	(32 913)	(61 145)	69 198
Cash and cash equivalents at beginning of the period		241 910	172 711	172 712
Cash and cash equivalents at end of the period	87%	208 997	111 566	241 910
Reconciled as follows:	-			
Cash and cash equivalents on hand		208 997	120 653	241 910
Bank overdraft	-	-	(9 087)	-
	-	208 997	111 566	241 910

EARNINGS ATTRIBUTABLE TO EQUITY HOLDERS

9.54%

8.09%

2.40%

28.80%

22.01%

7.63%

1.96%

28.40%

21.68%

	% change	Unaudited six months ended 31 December 2012 R'000	Unaudited six months ended 31 December 2011 R'000	Audited year ended 30 June 2012 R'000
dinary shares in		269 154 524	267 458 718	268 231 817
eference shares in		16 638 000	16 638 000	16 638 000
rage number of s		268 894 005	265 332 341	267 276 657

334 333 038

59 529

(929)

308

35

58 943

22.14

17.81

26.38

21.22

21.92

17.63

26.16

21.04

312 530 939

54 344

(137)

(166)

54 041

20.48

17.39

20.48

17.39

20.37

17.29

20.37

17.29

332 384 302

164 506

(1 175)

(13 162)

(566)

(810)

148 793

61.55

52.31

49.49#

64.82

52.31

55.67

47.58

44.77#

58.94

47.58

COMMENTARY

ACCOUNTING POLICIES AND BASIS OF PREPARATION

The condensed consolidated financial statements for the six months ended 31 December 2012 are prepared in accordance with the requirements of International Financial Reporting Standards ("IFRS"), IAS 34 - Interim Financial Reporting, the SAICA Financial Reporting Guides as issued by the Accounting Practices Committee, the JSE Limited Listings Requirements, and the South African Companies Act 71 of 2008, as amended. The condensed consolidated interim financial statements are prepared on the historical cost basis and the accounting policies are consistent with those adopted and applied for the year ended 30 June 2012 in terms of IFRS

NATURE OF BUSINESS

AfroCentric Investment Corporation Limited ("AfroCentric") is a black-controlled, diversified investment holding company. It is listed on the Johannesburg Securities Exchange ("JSE") in the Healthcare Sector under the code: ACT. The Group's preference shares are also listed on the JSE under the code: ACTP.

AfroCentric holds a substantial majority stake in AfroCentric Health Limited ("AHL"), formerly Lethimvula Investments Limited. During the six months ended 31 December 2012, AfroCentric increased its holding in AHL to 93.64% (June 2012: 93.17%) through the purchase of minority shareholdings in that company. AfroCentric continues to engage with AHL shareholders who wish to offer their AHL shares for sale. AHL owns 100% of the issued share capital in Medscheme Holdings (Pty) Limited ("Medscheme"), a multi-medical scheme administrator and managed care provider. As the largest health risk management services provider and third largest medical scheme administrator in South Africa, Medscheme's focus is to achieve sustainability through innovation, effective health risk management, complemented by a relentless drive for operational and service efficiency. Medscheme has over 3.2 million lives under management. Medscheme's healthcare management expertise has been gained over 41 years, which includes several years of experience with the Government Employees Medical Scheme ("GEMS"). Although Medscheme is essentially a South African enterprise, the Group has a meaningful presence in Botswana, Namibia, Mauritius, Swaziland and Zimbabwe. Medscheme's operations in Mauritius provide an excellent platform for further international expansion and AHL continues to explore other opportunities on the African continent and elsewhere. Health Management and technical support services are provided to clients in the Republic of Ireland out of Mauritius.

AfroCentric has a 27.3% non-controlling interest in JSE-listed Jasco Electronics Holdings Limited ("Jasco"). Jasco provides solutions, services and products to customers through three core verticals: Information and Communication Technologies, Industry Solutions and Energy Solutions. One of Jasco's investments is Malesela Taihan Electric Cables (M-Tec). M-Tec is a leading manufacturer and distributor of fibre-optic cable including a wide range of power and telecom cables, serving inter alia, infrastructural development demands in the South African and African continental markets. Further information on Jasco can be found on the JSE lists under the code: JSC

AfroCentric's exploration and prospecting relationship with Rio Tinto PLC continues in terms of the Relationship and Strategic Cooperation Agreement (RSCA).

OPERATIONAL REVIEW

AfroCentric's operating profits amounted to R135.2 million during the period under review (2011: R103 million) an increase of 31%. The improved profitability arises primarily from AHL's increased revenue growth from expanding operations and continuing efficiency improvements in the Administration and Health Risk Management business. AHL's administration and managed care contracts are reviewed annually in January and accordingly profits of AHL are favourably weighted towards the period January-June in each year. Medscheme also secured GEMS administration contracts for contribution and debt management as well as the correspondence contract in 2012. These contracts also contributed to the growth in earnings for the six months ended 31 December 2012. AHL's financial position at 31 December 2012, suggests that all warranty provisions are likely to be satisfied through which the final price of the AHL investment will be determined.

Operating costs		(687 239)	(566 807)	(1 188 960)	Weighted average number of
Operating profit	31.00%	135 183	103 200	259 301	shares for diluted EPS including shares for share-based awards
Other income		4 482	10 965	14 894	Shares for share-based awards
Net finance cost		(893)	(1 701)	3 371	Basic earnings
Share of profit from associates		7 091	4 906	14 842	Adjusted by:
Profit before impairment and		145 863	117 370	292 408	- Fair value (gain) impairment of
amortisation					investment
Fair value gain (impairment) of investment		929	-	1 175	- Reversal of loan impairments
Fair value adjustment on investment in		(308)	-	13 162	 Fair value adjustment of investment in associate
associate IFRS 2 compliance adjustment (Notes		(11 402)	-	(9 357)	 Loss/profit on disposal of assets
1, 2 & 3)					- Fair value adjustments (other)
Depreciation		(17 744)	(19 293)	(38 128)	Headline earnings
Amortisation of intangible assets		(17 606)	(17 359)	(36 356)	Headine earnings
Profit before income tax	23.55%	99 732	80 718	222 904	Earnings per share (cents)
Income tax expense		(30 917)	(21 783)	(42 523)	 Attributable to ordinary shares
Profit for the year	16.76%	68 815	58 935	180 381	(cents)
Other comprehensive income		-	-	-	 Diluted earnings per share
Total comprehensive income for		68 815	58 935	180 381	(cents) (as reported) (Note 2)
the year					 Diluted earnings per share
Attributable to:					(cents)
Equity holders of the Parent	9.54%	59 529	54 344	164 506	 Normalised earnings per share
Non-controlling interest		9 286	4 591	15 875	(cents) (Note 3)
		68 815	58 935	180 381	 Diluted normalised earnings

Note 1: Actuarially determined cost of share-based awards in each period reserved for selected executives of Afrocentric Health Limited (AHL) in terms of the 2009 Acquisition Agreement, categorised for disclosure herein in terms of IFRS 2.

Note 2: The above non-cash deduction from Group profits in 2012 amounting to R9 357 was inadvertently added back for purposes of determining diluted earnings per share and diluted headline earnings per share for the year ended 30 June 2012. The calculations relative to this matter have accordingly been revised and are correctly disclosed and described in the table of Earnings Attributable to Equity Holders.

Note 3: Given the non-cash nature of the IFRS 2 compliance adjustment and also the specific and non-recurring nature of the executive awards, the Board concluded that a more meaningful measure of the company's performance is revealed by adding back the IFRS 2 compliance adjustment which is refered to herein as "normalised earnings" These normalised earnings are also disclosed and described in the table of Earnings

Revised as per Note 2 Attributable to Equity Holders.

SEGMENTAL ANALYSIS

	UNAUDITED INTERIM RESULTS for the six months ended 31 December 2012			UNAUDITED INTERIM RESULTS for the six months ended 31 December 2011			AUDITED RESULTS for the year ended 30 June 2012		
	Revenue R'000	Profit before tax R'000	Total assets R'000	Revenue R'000	Profit before tax R'000	Total assets R'000	Revenue	Profit before tax	Total assets
Healthcare administration Electronics (including investment	822 422	119 708 3 881	1 064 448	670 007	72 152 2 650	806 941	1 448 261	217 086 5 988	977 763
income) Treasury activities Other (including inter-segment	-	3 705	113 559	-	3 915	110 517	-	7 758	119 561
elimination)	- 822 422	(27 562) 99 732	217 559 1 395 566	- 670 007	2 001 80 718	266 346 1 183 804	- 1 448 261	(7 928)	265 976 1 363 300

By Order of the Board Yolandi Van Zweel

Acting company secretary Johannesburg

Directors

AT Mokgokong** (Chairperson), D Dempers (CEO)***, WRC Holmes (CFO)***, NB Bam**, B Joffe**, JM Kahn** MJ Madungundaba**, Y Masithela*, G Napier*, MI Sacks** *independent non-executive **non-executive ***executive

Registered Office 37 Conrad Rd

Florida North 1709 Sponsor Sasfin Capital (A division of Sasfin Bank Limited)

AfroCentric Investment Corporation Limited Registration number 1988/000570/06 JSE Code: ACT, ACTP ISIN: ZAE 000078416, ZAE 000082269 ("AfroCentric" or "the Company" or "the Group")

AfroCentric's investment in the listed entity Jasco vielded earnings and investment income for the six months ended 31 December 2012 of R7.3 million (2011: R4.9 million). Further information on Jasco's earnings, operations and prospects are available on SENS under JSE Code: JSC.

AfroCentric has entered into a contract with Rio Tinto for a significant minority interest in a new iron-ore exploration joint venture project on terms consistent with the provisions of the continuing RSCA and subject to DMR approvals.

FINANCIAL RESULTS

Profit before tax for the six month period ended 31 December 2012, after deducting the IFRS compliance adjustment, (more fully explained in Notes 1, 2 and 3 to the Condensed Consolidated Statement of Comprehensive Income) increased by 23.55%. Profits after tax attributable to equity holders increased by 9.54% and earnings per share and headline earnings per share increased by 8.09% and 7.63% respectively.

Shareholders are once again reminded that all of the warranties provided for in the 2009 AHL Acquisition Agreement ("the agreement") will be measured against actual performance of AHL as at 30th June 2013. To the extent that all of the warranties are fulfilled and depending on the percentage of AHL shares owned by AfroCentric at that date, a maximum of 138.5 million ordinary shares, referred to as "contingent shares to be issued" in the 2012 Integrated Report, will be issued to the original vendors on or before 30 September 2013 together with past distributions attributable to such shares.

In addition, in the second quarter of the 2014 financial year, AfroCentric will notify preference shareholders of the means by which they can elect to convert their preference shares into ordinary shares. The election to convert must be made prior to 31st December 2013 in terms of the preference share covenants. Preference shares not converted within the specified period will be redeemed by the company.

PROSPECTS

While the Group's investment in AHL has generally been heartening, the progress and performance of Jasco during the period under review has been disappointing. The board nevertheless recognises the talent and commitment of both management teams, and remains confident of the growth prospects of each of the core businesses. The Board will proceed to assess new opportunities which satisfy the criteria of the Board Investment Committee, including providing continual counsel to group management on operational matters and efficiencies

SUBSEQUENT EVENTS

No significant events have occurred in the period between the reporting date and the date of this announcement.

DIRECTORS

During the period under review NB Bam retired as Chairperson, but she will continue to act as a non-executive director of the company. Dr AT Mokgokong was appointed Chairperson and D Dempers was appointed Chief Executive Officer. There were no further changes to the AfroCentric Board.

DIVIDENDS

The policy of the Board is to review profits available for distribution to shareholders at the end of each financial year. Accordingly no distribution has been considered at this time.

BASIS OF PREPARATION

The unaudited interim results have been prepared under the supervision of Mr WRC Holmes CA(SA), in his capacity as the Group Chief Financial Officer.

www.afrocentric.za.com

Tascom